PharmaPoint: Prostate Cancer - Canada Drug Forecast and Market Analysis to 2022


#163766

163pages

GlobalData

$ 4995

In Stock

PharmaPoint: Prostate Cancer - Canada Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, “PharmaPoint: Prostate Cancer - Canada Drug Forecast and Market Analysis to 2022”. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’ Xtandi (enzalutamide) will drive strong market growth over the next decade. 

These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naïve mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. 

For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.

In Canada, prostate cancer is diagnosed following an abnormal DRE, elevated PSA levels detected during routine screening, or a patients’ presentation with symptoms that leads to either of these tests. A suspected diagnosis of prostate cancer is confirmed by TRUS-guided multiple core needle biopsies, and bone metastases are detected using a CT scan or bone scan. 

The uptake of routine PSA screening has been high in Canada, but some Canadian physicians surveyed by GlobalData reported that they plan to decrease their use of routine screening in response to the recent USPSTF recommendation against it (Baade et al., 2009).

Scope
  • Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Canada including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Canada from 2012 to 2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Canada Prostate cancer market.
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Prostate cancer drug performance in Canada
  • Obtain sales forecast from 2012-2022 in Canada
Table of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
2.3 Upcoming Related Reports 11

3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 12
3.1.3 Prognosis 13
3.1.4 Quality of Life 14
3.2 Symptoms 14

4 Disease Management 15
4.1 Diagnosis and Referral Overview 15
4.2 Treatment Overview 17
4.2.1 Conservative Management Strategies 21
4.2.2 Localized Treatments 22
4.2.3 Hormone Therapy 23
4.2.4 Drug Therapies 25
4.3 Canada 26
4.3.1 Diagnosis 26
4.3.2 Clinical Practice 26

5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 29
5.3 Product Profiles - Major Brands, Hormone Therapies 32
5.3.1 Zoladex (goserelin acetate) 32
5.3.2 Lupron Depot (leuprolide acetate) 35
5.3.3 Eligard (leuprolide acetate) 39
5.3.4 Trelstar (triptorelin acetate) 43
5.3.5 Firmagon (degarelix) 46
5.3.6 Casodex (bicalutamide) 49
5.4 Product Profiles - Major Brands, Chemotherapies 53
5.4.1 Taxotere (docetaxel) 53
5.4.2 Jevtana (cabazitaxel) 56
5.5 Product Profiles - Major Brands, Therapeutic Vaccines 60
5.5.1 Provenge (sipuleucil-T) 60
5.6 Product Profiles - Major Brands, Targeted Therapies 65
5.6.1 Zytiga (abiraterone acetate) 65
5.6.2 Xtandi (enzalutamide) 69
5.7 Product Profiles - Major Brands, Bone Therapies 73
5.7.1 Xgeva (denosumab) 73
5.7.2 Zometa (zoledronic acid) 76
5.8 Other Marketed Hormone and Drug Therapies 79

6 Opportunity and Unmet Need 80
6.1 Overview 80
6.2 Efficacy at Prolonging Overall Survival 81
6.3 Safety 81
6.4 Mitigation of Symptoms 82
6.5 Cost 82
6.6 Convenient Routes of Administration 82
6.7 Accurate Diagnostic Tests and Surveillance Tools 83
6.8 Unmet Needs Gap Analysis 83
6.9 Opportunity: Targeting Early-Stage, Hormone-Sensitive Prostate Cancer 85

7 Pipeline Assessment 86
7.1 Overview 86
7.2 Promising Drugs in Clinical Development 87
7.2.1 Cabozantinib 89
7.2.2 Custirsen Sodium 93
7.2.3 Sprycel (dasatinib) 98
7.2.4 Yervoy (ipilimumab) 102
7.2.5 Orteronel 107
7.2.6 Alpharadin (radium-223 chloride) 111
7.2.7 Tasquinimod 116
7.2.8 ProstVac (Vaccinia-PSA-TRICOM/Fowlpox-PSA-TRICOM) 120

8 Market Outlook 125
8.1 Canada 125
8.1.1 Forecast 125
8.1.2 Key Events 128
8.1.3 Drivers and Barriers 128

9 Appendix 130
9.1 Bibliography 130
9.2 Abbreviations 143
9.3 Methodology 146
9.4 Forecasting Methodology 146
9.4.1 Number of Prostate Cancer Patients Currently Seeking Treatment 146
9.4.2 Percent Drug-treated Patients 147
9.4.3 Percent Hormone Therapy-Treated Patients 147
9.4.4 Drugs Included in Each Therapeutic Class 147
9.4.5 General Pricing Assumptions 148
9.4.6 Individual Drug Assumptions 150
9.4.7 Generic Erosion 158
9.4.8 Pricing of Pipeline Agents 158
9.5 Physicians and Specialists Included in This Study 160
9.6 Survey of Prescribing Physicians 160
9.7 About the Authors 161
9.7.1 Authors 161
9.7.2 Global Head of Healthcare 162
9.8 About GlobalData 163
9.9 Contact Us 163
9.10 Disclaimer 163

Table 1: Stage Distribution of Prostate Cancer at Diagnosis in Selected Major Markets 13
Table 2: Global Variations in Recommendations on Routine PSA Screening 15
Table 3: Most Commonly Followed Treatment Guidelines for Prostate Cancer, 2012 18
Table 4: Most Commonly Prescribed Drugs for Prostate Cancer by Class in the Global Markets, 2012 20
Table 5: Leading Treatments for Prostate Cancer, 2012 31
Table 6: Product Profile - Zoladex 33
Table 7: Zoladex SWOT Analysis, 2012 35
Table 8: Product Profile - Lupron Depot 36
Table 9: Lupron Depot SWOT Analysis, 2012 38
Table 10: Product Profile - Eligard 40
Table 11: Eligard SWOT Analysis, 2012 42
Table 12: Product Profile - Trelstar 44
Table 13: Trelstar SWOT Analysis, 2012 45
Table 14: Product Profile - Firmagon 46
Table 15: Firmagon SWOT Analysis, 2012 48
Table 16: Product Profile - Casodex 50
Table 17: Casodex SWOT Analysis, 2012 52
Table 18: Product Profile - Taxotere 54
Table 19: Taxotere SWOT Analysis, 2012 56
Table 20: Product Profile - Jevtana 57
Table 21: Jevtana SWOT Analysis, 2012 59
Table 22: Product Profile - Provenge 60
Table 23: Provenge SWOT Analysis, 2012 64
Table 24: Product Profile - Zytiga 66
Table 25: Zytiga SWOT Analysis, 2012 68
Table 26: Product Profile - Xtandi 70
Table 27: Xtandi SWOT Analysis, 2012 72
Table 28: Product Profile - Xgeva 74
Table 29: Xgeva SWOT Analysis, 2012 76
Table 30: Product Profile - Zometa 77
Table 31: Zometa SWOT Analysis, 2012 79
Table 32: Summary of Other Marketed Hormone and Drug Therapies, 2012 79
Table 33: Overall Unmet Needs, Hormone-Sensitive Prostate Cancer - Current Level of Attainment 80
Table 34: Overall Unmet Needs, CRPC - Current Level of Attainment 81
Table 35: Clinical Unmet Needs - Gap Analysis, 2012 84
Table 36: Prostate Cancer - Phase III Pipeline, 2012 87
Table 37: Comparison of Therapeutic Classes in Development for Prostate Cancer, 2012 87
Table 38: Product Profile - Cabozantinib 89
Table 39: Cabozantinib SWOT Analysis, 2012 93
Table 40: Product Profile - Custirsen Sodium 94
Table 41: Custirsen Sodium SWOT Analysis, 2012 97
Table 42: Product Profile - Sprycel 98
Table 43: Sprycel SWOT Analysis, 2012 102
Table 44: Product Profile - Yervoy 103
Table 45: Yervoy SWOT Analysis, 2012 107
Table 46: Product Profile - Orteronel 108
Table 47: Orteronel SWOT Analysis, 2012 111
Table 48: Product Profile - Alpharadin (radium-223 chloride) 112
Table 49: Alpharadin SWOT Analysis, 2012 115
Table 50: Product Profile - Tasquinimod 116
Table 51: Tasquinimod SWOT Analysis, 2012 119
Table 52: Product Profile - ProstVac (Vaccinia-PSA-TRICOM/Fowlpox-PSA-TRICOM) 120
Table 53: ProstVac SWOT Analysis, 2012 124
Table 54: Sales Forecasts ($m) for Prostate Cancer in Canada, 2012-2022 126
Table 55: Key Events Impacting Sales for Prostate Cancer in Canada, 2012-2022 128
Table 56: Prostate Cancer Market in Canada - Drivers and Barriers, 2012 128
Table 57: Physicians Surveyed, By Country 160
Figure 1: General Treatment Algorithm for Prostate Cancer, 2012 19
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Prostate Cancer, 2012-2022 88
Figure 3: Sales for Prostate Cancer in Canada by Drug Class, 2012-2022 127